Results 41 to 50 of about 284 (126)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects

Drug Design, Development and Therapy, 2019
Patricia N Sidharta,1 Meggane Melchior,1 Martin K Kankam,2 Jasper Dingemanse1 1Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil CH-4123, Switzerland; 2Vince and Associates Clinical Research, Overland Park, KS 66211, USA ...
Sidharta PN, Melchior M, Kankam MK, Dingemanse J   +3 more
doaj  

Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

British Journal of Pharmacology, Volume 181, Issue 3, Page 319-339, February 2024.
Abstract Resistant hypertension is associated with an exceedingly high cardiovascular risk and there remains an unmet therapeutic need driven by pathophysiologic pathways unaddressed by guideline‐recommended therapy. While spironolactone is widely considered as the preferable fourth‐line drug, its broad application is limited by its side effect profile,
Omar Azzam, Sayeh Heidari Nejad, Revathy Carnagarin, Janis M. Nolde, Marcio Galindo‐Kiuchi, Markus P. Schlaich   +5 more
wiley   +1 more source

Effect of Fourth-Line Antihypertensive Therapy on Clinic Systolic Blood Pressure in Resistant Hypertension: A Systematic Review and Meta-Analysis

Blood Pressure
Introduction/Background Resistant hypertension (rHTN) is defined as uncontrolled blood pressure despite ≥3 antihypertensives, including a diuretic.
Taha Alam, Muhammad Saad, Taha Ibrahim, Dhvanit Rajdeep, Zainab Jamshaid, Muhammad Hassan, Noor Un Nisa, Muhammad Hussain, Sohaima Kamal, Hira Arshad Jawed, Rafiullah Hotak   +10 more
doaj   +1 more source

Management of nocturnal hypertension: An expert consensus document from Chinese Hypertension League

The Journal of Clinical Hypertension, Volume 26, Issue 1, Page 71-83, January 2024.
Abstract Nocturnal hypertension is highly prevalent among Chinese and Asian populations, which is mainly attributed to high salt intake and high salt sensitivity. Nocturnal hypertension increases the risk of cardiovascular and all‐cause mortality, independent of daytime blood pressure (BP).
Jing Liu, Yan Li, Xinjun Zhang, Peili Bu, Xueping Du, Lizheng Fang, Yingqing Feng, Yifang Guo, Fei Han, Yinong Jiang, Yuming Li, Jinxiu Lin, Min Liu, Wei Liu, Mingzhi Long, Jianjun Mu, Ningling Sun, Hao Wu, Jianhong Xie, Jingyuan Xie, Liangdi Xie, Jing Yu, Hong Yuan, Yan Zha, Yuqing Zhang, Shanzhu Zhu, Jiguang Wang, Chinese Hypertension League expert consensus committee on the management of nocturnal hypertension   +27 more
wiley   +1 more source

New and developing pharmacotherapies for hypertension

, 2022
Introduction: Despite the significant contribution of hypertension to the global burden of disease, disease control remains poor worldwide. Considering this unmet clinical need, several new antihypertensive drugs with novel mechanisms of action are under
Chiappetta, Diego Andrés, Diego A Chiappetta, Carranza, Maria Andrea, Andrea Carranza, Christian Höcht, Ariel Héctor Polizio, Marcela A Morettón, Marcelo Roberto Choi, Miguel A Allo, Moretton, Marcela Analía, Choi, Marcelo Roberto, Höcht, Christian, Allo, Miguel A, Polizio, Ariel Héctor   +13 more
core   +1 more source

Endothelin receptor antagonists in chronic kidney disease [PDF]

Endothelin-1 is a potent vasoconstrictor that has diverse physiological functions in the kidney, including in the regulation of blood flow and glomerular filtration, electrolyte homeostasis and endothelial function.
Smeijer, J. David; id_orcid, Noronha, Irene L., Heerspink, Hiddo J.L., Dhaun, Neeraj, Liew, Adrian, Kohan, Donald E.   +5 more
core   +3 more sources

Update on Endothelin Receptor Antagonists in Hypertension

, 2018
To review the most recent data on the development of endothelin receptor antagonists (ERAs) for the treatment of hypertension and the management of diabetic nephropathy RECENT FINDINGS: Recent reviews and meta-analyses of experimental and clinical data ...
Michel Burnier, Burnier, M.
core   +1 more source

Aprocitentan mitigates ischemia reperfusion induced kidney injury in rats by attenuating inflammation and pyroptosis through suppressing NF-κB/NLRP3/caspase-1 signaling pathway

Introduction and aim. Renal ischemia-reperfusion (I/R) injury is a primary cause of acute kidney injury (AKI). The NF-κB/NLRP3/caspase-1 signaling system is crucial for I/R-induced kidney damage, which leads to inflammation, pyroptosis, and tissue damage.
Tweij, Thu-Alfeqar R., Alfatli, Layla Ameen Rasheed   +1 more
core   +1 more source

New Therapy Update Aprocitentan an Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension

Resistant hypertension (RH) is the state of uncontrolled blood pressure in the face of ostensibly optimal pharmacological intervention. It accounts for roughly one in six cases of hypertension, and is associated with more severe morbidity and mortality ...
Airo, Michael, Frishman, WIlliam H., Aronow, Wilbert S.   +2 more
core   +1 more source

The New Drugs in the Treatment of Hypertension and Resistant Hypertension: A Review of Therapies

Advancements in pharmacotherapy for hypertension (HTN) have led to the development of new drug classes and innovative supportive treatments. Aprocitentan, an endothelin receptor antagonist, has demonstrated promising effects in managing resistant ...
Lorenc, Tomasz, Marcinkowski, Krzysztof, Michalik, Maciej, Muras, Mateusz Szymon, Mikszta, Jakub, Marcinkowska, Julia, Mikszta, Natalia   +6 more
core   +2 more sources